Please check your internet connection and try again.
# Mylot%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525250at
## Overview
Mylot%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525250at is a brand name for trifluridine/tipiracil. Trifluridine is an antiviral agent, and tipiracil is a thymidine phosphorylase inhibitor that increases trifluridine bioavailability.
## Primary Indications
Treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with, or are not candidates for, fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.
## Adult Dosing
The recommended dose is one 35.4 mg/m%C2%B2 tablet orally every 12 hours on days 1 through 5 of each 28-day cycle, followed by 2 days of rest (Days 6 and 7). Treatment is continued until disease progression or unacceptable toxicity.
## Pediatric Dosing
Information regarding pediatric use is not established.
## Dose Adjustments
Dose modifications may be required for neutropenia, diarrhea, and other toxicities. Refer to the full prescribing information for detailed dose reduction guidelines.
## Contraindications
None.
## Adverse Effects
Common adverse effects include neutropenia, thrombocytopenia, anemia, fatigue, nausea, decreased appetite, diarrhea, vomiting, and stomatitis.
## Key Drug Interactions
* **CYP3A4 inhibitors/inducers:** May affect trifluridine concentrations.
* **Other myelosuppressive agents:** Increased risk of myelosuppression.
## Monitoring
* Complete blood counts (CBC) with differential and platelet count prior to initiation and regularly during treatment.
* Monitor for signs and symptoms of gastrointestinal toxicity (diarrhea, nausea, vomiting, stomatitis).
* Monitor for signs of infection.
## Clinical Pearls
* Administer Mylot%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525250at orally.
* Due to the risk of myelosuppression, frequent monitoring of blood counts is essential.
* Manage gastrointestinal toxicities promptly.
***
*Disclaimer: This information is intended for healthcare professionals. Always verify current prescribing information and consult with relevant resources before making clinical decisions.*
